Genor Biopharma Holdings Dividends and Buybacks
Dividend criteria checks 0/6
Genor Biopharma Holdings does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.0004%
Buyback Yield
Total Shareholder Yield | -0.0004% |
Future Dividend Yield | 0% |
Dividend Growth | n/a |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment
Jun 20Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation
May 29We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully
Dec 29We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely
Dec 21Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?
Sep 05We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth
Dec 03Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation
Aug 28Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?
May 10Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if 6998's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6998's dividend payments have been increasing.
Dividend Yield vs Market
Genor Biopharma Holdings Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (6998) | n/a |
Market Bottom 25% (HK) | 3.2% |
Market Top 25% (HK) | 8.1% |
Industry Average (Biotechs) | 1.1% |
Analyst forecast (6998) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate 6998's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6998's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate 6998's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 6998 has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/21 11:46 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genor Biopharma Holdings Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ziyi Chen | Goldman Sachs |
Yue-Kwong Lui | Jefferies LLC |
Ling Wang | J.P. Morgan |